Ocular Therapeutix IncNASDAQ:OCUL
- LAST PRICE4.9100
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 4.9100
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | OCUL |
|---|---|---|
| 09:32 ET | 20073 | 4.96 |
| 09:34 ET | 19888 | 5.05 |
| 09:36 ET | 20208 | 5.148 |
| 09:38 ET | 13348 | 5.25 |
| 09:39 ET | 40814 | 5.3894 |
| 09:41 ET | 8141 | 5.32 |
| 09:43 ET | 11610 | 5.33 |
| 09:45 ET | 16254 | 5.29 |
| 09:48 ET | 1750 | 5.24 |
| 09:50 ET | 1600 | 5.24 |
| 09:52 ET | 3932 | 5.2 |
| 09:54 ET | 1778 | 5.19 |
| 09:56 ET | 4569 | 5.16 |
| 09:57 ET | 2092 | 5.1201 |
| 09:59 ET | 900 | 5.06 |
| 10:01 ET | 7813 | 5.065 |
| 10:03 ET | 4166 | 5.0601 |
| 10:06 ET | 3803 | 5.04 |
| 10:08 ET | 41835 | 5.02 |
| 10:10 ET | 300 | 5.025 |
| 10:12 ET | 3527 | 5.07 |
| 10:14 ET | 586 | 5.075 |
| 10:15 ET | 1140 | 5.0738 |
| 10:17 ET | 1456 | 5.04 |
| 10:19 ET | 8372 | 5.01 |
| 10:21 ET | 14319 | 5.03 |
| 10:24 ET | 6388 | 5.02 |
| 10:26 ET | 28497 | 4.94 |
| 10:28 ET | 2297 | 4.9 |
| 10:30 ET | 4456 | 4.9 |
| 10:32 ET | 5314 | 4.94 |
| 10:33 ET | 1300 | 4.91 |
| 10:35 ET | 1289 | 4.925 |
| 10:37 ET | 1555 | 4.91 |
| 10:39 ET | 1924 | 4.93 |
| 10:42 ET | 700 | 4.931 |
| 10:44 ET | 3012 | 4.91 |
| 10:46 ET | 3900 | 4.87 |
| 10:48 ET | 1318 | 4.86 |
| 10:50 ET | 200 | 4.88 |
| 10:51 ET | 1550 | 4.87 |
| 10:53 ET | 300 | 4.86 |
| 10:55 ET | 300 | 4.86 |
| 10:57 ET | 5299 | 4.88 |
| 11:00 ET | 305 | 4.88 |
| 11:02 ET | 200 | 4.88 |
| 11:04 ET | 6212 | 4.875 |
| 11:06 ET | 615 | 4.86 |
| 11:09 ET | 398 | 4.86 |
| 11:11 ET | 8607 | 4.85 |
| 11:13 ET | 6450 | 4.87 |
| 11:15 ET | 1600 | 4.875 |
| 11:18 ET | 1710 | 4.89 |
| 11:22 ET | 7521 | 4.95 |
| 11:24 ET | 2800 | 4.945 |
| 11:26 ET | 100 | 4.945 |
| 11:27 ET | 300 | 4.945 |
| 11:29 ET | 300 | 4.96 |
| 11:31 ET | 1010 | 4.93 |
| 11:33 ET | 1190 | 4.91 |
| 11:36 ET | 900 | 4.91 |
| 11:38 ET | 931 | 4.9018 |
| 11:40 ET | 2103 | 4.89 |
| 11:42 ET | 2500 | 4.89 |
| 11:44 ET | 1900 | 4.88 |
| 11:45 ET | 800 | 4.89 |
| 11:47 ET | 3250 | 4.96 |
| 11:49 ET | 200 | 4.97 |
| 11:51 ET | 1335 | 4.985 |
| 11:54 ET | 1780 | 4.98 |
| 11:56 ET | 428 | 4.98 |
| 11:58 ET | 100 | 4.975 |
| 12:00 ET | 3318 | 4.95 |
| 12:02 ET | 300 | 4.95 |
| 12:03 ET | 17243 | 4.98 |
| 12:09 ET | 18615 | 4.99 |
| 12:12 ET | 2000 | 4.97 |
| 12:14 ET | 600 | 4.98 |
| 12:16 ET | 1918 | 4.97 |
| 12:18 ET | 3200 | 4.97 |
| 12:20 ET | 700 | 4.97 |
| 12:21 ET | 2206 | 4.96 |
| 12:23 ET | 1877 | 4.965 |
| 12:25 ET | 400 | 4.95 |
| 12:27 ET | 380 | 4.95 |
| 12:30 ET | 1000 | 4.965 |
| 12:32 ET | 1500 | 4.965 |
| 12:34 ET | 200 | 4.95 |
| 12:36 ET | 5792 | 4.95 |
| 12:38 ET | 2041 | 4.93 |
| 12:39 ET | 600 | 4.94 |
| 12:41 ET | 1500 | 4.91 |
| 12:43 ET | 300 | 4.91 |
| 12:45 ET | 700 | 4.91 |
| 12:48 ET | 1749 | 4.9 |
| 12:50 ET | 1500 | 4.9 |
| 12:52 ET | 3274 | 4.8854 |
| 12:54 ET | 1500 | 4.86 |
| 12:56 ET | 700 | 4.865 |
| 12:57 ET | 500 | 4.85 |
| 12:59 ET | 800 | 4.86 |
| 01:01 ET | 600 | 4.86 |
| 01:03 ET | 600 | 4.855 |
| 01:06 ET | 1000 | 4.865 |
| 01:08 ET | 5348 | 4.88 |
| 01:10 ET | 100 | 4.88 |
| 01:12 ET | 2496 | 4.85 |
| 01:14 ET | 200 | 4.865 |
| 01:15 ET | 100 | 4.85 |
| 01:17 ET | 600 | 4.8683 |
| 01:19 ET | 953 | 4.87 |
| 01:21 ET | 500 | 4.86 |
| 01:24 ET | 2400 | 4.87 |
| 01:26 ET | 600 | 4.86 |
| 01:28 ET | 3825 | 4.86 |
| 01:30 ET | 800 | 4.8683 |
| 01:32 ET | 2952 | 4.8812 |
| 01:33 ET | 100 | 4.88 |
| 01:35 ET | 300 | 4.85 |
| 01:37 ET | 300 | 4.865 |
| 01:39 ET | 400 | 4.87 |
| 01:42 ET | 2470 | 4.86 |
| 01:44 ET | 2511 | 4.85 |
| 01:46 ET | 600 | 4.86 |
| 01:48 ET | 1950 | 4.8698 |
| 01:50 ET | 3000 | 4.85 |
| 01:51 ET | 17489 | 4.79 |
| 01:53 ET | 700 | 4.8 |
| 01:55 ET | 1778 | 4.79 |
| 01:57 ET | 4800 | 4.8 |
| 02:02 ET | 400 | 4.81 |
| 02:04 ET | 1400 | 4.8 |
| 02:06 ET | 1175 | 4.8 |
| 02:08 ET | 1258 | 4.8 |
| 02:09 ET | 400 | 4.8 |
| 02:11 ET | 460 | 4.8074 |
| 02:13 ET | 400 | 4.79 |
| 02:15 ET | 856 | 4.79 |
| 02:18 ET | 18581 | 4.75 |
| 02:20 ET | 1100 | 4.75 |
| 02:22 ET | 843 | 4.74 |
| 02:24 ET | 5965 | 4.77 |
| 02:26 ET | 3090 | 4.8 |
| 02:27 ET | 555 | 4.8 |
| 02:29 ET | 644 | 4.79 |
| 02:31 ET | 1450 | 4.76 |
| 02:33 ET | 200 | 4.76 |
| 02:36 ET | 1714 | 4.75 |
| 02:38 ET | 8798 | 4.75 |
| 02:40 ET | 1200 | 4.75 |
| 02:42 ET | 1300 | 4.73 |
| 02:44 ET | 4643 | 4.74 |
| 02:45 ET | 13590 | 4.84 |
| 02:47 ET | 10767 | 4.82 |
| 02:49 ET | 2427 | 4.82 |
| 02:51 ET | 1057 | 4.815 |
| 02:54 ET | 3234 | 4.8398 |
| 02:56 ET | 10048 | 4.84 |
| 02:58 ET | 912 | 4.83 |
| 03:00 ET | 1400 | 4.84 |
| 03:02 ET | 2739 | 4.8301 |
| 03:03 ET | 7300 | 4.847 |
| 03:05 ET | 3569 | 4.83 |
| 03:07 ET | 1300 | 4.81 |
| 03:09 ET | 2200 | 4.8 |
| 03:12 ET | 2300 | 4.8 |
| 03:14 ET | 2051 | 4.8 |
| 03:16 ET | 2870 | 4.8 |
| 03:18 ET | 3414 | 4.85 |
| 03:20 ET | 137 | 4.86 |
| 03:21 ET | 200 | 4.86 |
| 03:23 ET | 3456 | 4.84 |
| 03:25 ET | 600 | 4.85 |
| 03:27 ET | 916 | 4.85 |
| 03:30 ET | 1503 | 4.86 |
| 03:32 ET | 4100 | 4.84 |
| 03:34 ET | 500 | 4.85 |
| 03:36 ET | 2520 | 4.89 |
| 03:38 ET | 37636 | 5 |
| 03:39 ET | 9223 | 4.945 |
| 03:41 ET | 3471 | 4.94 |
| 03:43 ET | 668 | 4.93 |
| 03:45 ET | 4840 | 4.92 |
| 03:48 ET | 6144 | 4.92 |
| 03:50 ET | 1100 | 4.92 |
| 03:52 ET | 6700 | 4.9 |
| 03:54 ET | 3337 | 4.895 |
| 03:56 ET | 11850 | 4.87 |
| 03:57 ET | 13687 | 4.865 |
| 03:59 ET | 74705 | 4.91 |
Yesterday
--JMP Securities Adjusts Ocular Therapeutix Price Target to $25 From $20, Maintains Market Outperform Rating, from 12 hours ago by MT Newswires
12 hours ago by MT Newswires--Jefferies Raises Price Target for Ocular Therapeutix to $6.50 From $5, Maintains Buy Rating, from 15 hours ago by MT Newswires
15 hours ago by MT Newswires
Aug 8, 2022
BRIEF-Ocular Therapeutix Reports Second Quarter 2022 Results , from 6:38PM ET on Monday Aug 08, 2022 by Thomson Reuters
6:38PM ET on Monday Aug 08, 2022 by Thomson ReutersBRIEF-Ocular Therapeutix™ Reports Second Quarter 2022 Financial Results And Business Update, from 6:38PM ET on Monday Aug 08, 2022 by Thomson Reuters
6:38PM ET on Monday Aug 08, 2022 by Thomson Reuters-- Earnings Flash (OCUL) OCULAR THERAPEUTIX Reports Q2 Revenue $12.3M, from 4:04PM ET on Monday Aug 08, 2022 by MT Newswires
4:04PM ET on Monday Aug 08, 2022 by MT Newswires
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Ocular Therapeutix Inc | 388.4M | -11.5x | --- |
EyePoint Pharmaceuticals Inc | 361.2M | -4.8x | --- |
SNDL Inc | 668.8M | -5.2x | --- |
Esperion Therapeutics Inc | 427.3M | -1.0x | --- |
Avadel Pharmaceuticals PLC | 372.5M | -4.7x | --- |
OptiNose Inc | 297.7M | -2.7x | --- |
Company Information
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of therapies for diseases and conditions of the eye. Its first commercial drug product, DEXTENZA, developed for the treatment of ocular inflammation and pain ophthalmic surgery and ocularitching associated with allergic conjunctivitis. Its earlier stage development assets include axitinib intravitreal implant (OTX-TKI), is under Phase I clinical trials for the treatment of wet AMD and other retinal diseases. Its travoprost intracameral implant (OTX-TIC) is under Phase II clinical trial to evaluate the reduction of intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension. It has also completed Phase II clinical trials for cyclosporine intracanalicular insert (OTX-CSI) for the chronic treatment of dry eye disease and dexamethasone intracanalicular insert (OTX-DED) for the short-term treatment of the signs and symptoms of dry eye disease.
Contact Information
- Headquarters
- 24 Crosby DriveBEDFORD, MA, United States 01730
- Phone
- 781-895-3235
- Fax
- 781-357-4001
Executives
- Independent Chairman of the Board
- Charles Warden
- Director
- Antony Mattessich
- Chief Financial Officer
- Donald Notman
- General Counsel
- Philip Strassburger
- Chief Medical Officer
- Rabia Ozden
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $377.9M |
|---|---|
Revenue (TTM) | $49.9M |
Shares Outstanding | 77.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.49 |
EPS | $-0.43 |
Book Value | $1.15 |
P/E Ratio | -11.5x |
Price/Sales (TTM) | 7.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -150.91% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
